Cephalon To File Gabitril Generalized Anxiety Disorder Claim By Mid-Year
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Cephalon plans to file an sNDA by mid-year for expanded use of its anti-seizure medication Gabitril to treat generalized anxiety disorder, pending the outcome of Phase III trials
You may also be interested in...
Nuvigil action date extension
FDA's revised user fee date for Cephalon's excessive daytime sleepiness agent Nuvigil (armodafinil) is April 30 following a 90-day extension. The agency deemed additional information, submitted in October, to be a major amendment to Cephalon's NDA. The firm maintains that it does not expect further delays and continues to expect a mid-2006 launch. Nuvigil is a follow-on compound to Cephalon's sleepiness agent Provigil (modafinil), which could see generic competition by mid-2006...
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
September 2010 Approvals
Product